⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443906 | 0.79 | — | — | |
| SCHEMBL295682 | 0.75 | — | — | |
| SCHEMBL57893 | 0.75 | — | — | |
| SCHEMBL27563466 | 0.72 | — | — | |
| SCHEMBL28968854 | 0.72 | — | — | |
| SCHEMBL61229 | 0.70 | — | — | |
| SCHEMBL4337113 | 0.70 | ALDH1A1 (0.31) | — | |
| SCHEMBL27516940 | 0.69 | CYP3A4 (0.39) | — | |
| SCHEMBL28053378 | 0.69 | — | — | |
| SCHEMBL1477464 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | claimed |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-12 | — | — | US | claimed |
| CN-109890822-B | Inhibitors of cellular metabolic processes | 安吉奥斯医药品有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | claimed |
| US-20210246137-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-08-12 | — | — | US | claimed |
| WO-2021158792-A1 | METHODS OF TREATING AUTOIMMUNE OR INFLAMMATORY DISEASES OR DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2021-08-12 | — | — | WO | claimed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | claimed |
| US-20190315740-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-10-17 | — | — | US | claimed |
| EP-3526220-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2019-08-21 | — | — | EP | claimed |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2019-08-01 | — | — | US | claimed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | claimed |
| EP-0946528-B1 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-04-09 | — | — | EP | claimed |
| CN-1246847-A | Nitrogen containing heteroaromatics as factor Xa inhibitors | DU PONT MERCK PHARMA (US) | 2000-03-08 | — | — | CN | claimed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | claimed |
| EP-0946528-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | claimed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | claimed |
| WO-1998028282-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0012822-B1 | 3,4-DISUBSTITUTED 2-PHENYLIMINO-IMIDAZOLIDINES, THEIR ACID ADDITION SALTS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR THEIR PRODUCTION | C.H. BOEHRINGER SOHN (DE) | 1982-12-01 | — | — | EP | claimed |
| EP-0012822-A1 | 3,4-Disubstituted 2-phenylimino-imidazolidines, their acid addition salts, pharmaceutical preparations containing them and process for their production | C.H. BOEHRINGER SOHN (DE) | 1980-07-09 | — | — | EP | claimed |